Online Program Home
  My Program

Abstract Details

Activity Number: 295 - Adaptive Designs and Interim Analyses
Type: Contributed
Date/Time: Tuesday, August 1, 2017 : 8:30 AM to 10:20 AM
Sponsor: Biopharmaceutical Section
Abstract #322659 View Presentation
Title: Earning Regulatory Approval for a Phase II/III Design: a Case Study from Start to Finish
Author(s): Adam Hamm*
Companies: Cytel, Inc.
Keywords: Adaptive Design ; Phase II/III ; Dose Selection ; Simulations
Abstract:

In this presentation, I will discuss my experience and present a case study that outlines the steps that were taken to achieve regulatory approval under a Special Protocol Assessment for a Phase II/III adaptive study with dose selection after an interim analysis. Topics discussed will include criteria for dose selection, statistical methods for the interim and final analyses, and statistical software used for simulations of the design. The evolution of discussions with the FDA after each review will also be discussed, along with lessons learned.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2017 program

 
 
Copyright © American Statistical Association